These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 37436376)

  • 1. Sickle Cell Disease and Thromboembolism: New Insights on the Pathophysiology, Diagnosis, and Treatment.
    Dobie G
    Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance.
    Conran N; De Paula EV
    Haematologica; 2020 Oct; 105(10):2380-2390. PubMed ID: 33054078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke and presence of patent foramen ovale in sickle cell disease.
    Aggeli C; Polytarchou K; Dimitroglou Y; Patsourakos D; Delicou S; Vassilopoulou S; Tsiamis E; Tsioufis K
    J Thromb Thrombolysis; 2021 Oct; 52(3):889-897. PubMed ID: 33638018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism.
    Hamali HA
    Hemoglobin; 2023 Nov; 47(6):205-214. PubMed ID: 38189099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombosis and sickle cell disease.
    De Franceschi L; Cappellini MD; Olivieri O
    Semin Thromb Hemost; 2011 Apr; 37(3):226-36. PubMed ID: 21455857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging functional microfluidic assays for the study of thromboinflammation in sickle cell disease.
    An R; Gurkan UA
    Curr Opin Hematol; 2022 Nov; 29(6):327-334. PubMed ID: 35916533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
    Nader E; Romana M; Connes P
    Front Immunol; 2020; 11():454. PubMed ID: 32231672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemostatic abnormalities in sickle cell disease.
    Lim MY; Ataga KI; Key NS
    Curr Opin Hematol; 2013 Sep; 20(5):472-7. PubMed ID: 23817169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel inflammatory role for platelets in sickle cell disease.
    Davila J; Manwani D; Vasovic L; Avanzi M; Uehlinger J; Ireland K; Mitchell WB
    Platelets; 2015; 26(8):726-9. PubMed ID: 25548984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology.
    Lizarralde-Iragorri MA; Shet AS
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
    Nader E; Conran N; Romana M; Connes P
    Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the Treatment of Sickle Cell Disease.
    Kapoor S; Little JA; Pecker LH
    Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging disease-modifying therapies for sickle cell disease.
    Carden MA; Little J
    Haematologica; 2019 Sep; 104(9):1710-1719. PubMed ID: 31413089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.
    Xu JZ; Thein SL
    Blood; 2022 May; 139(20):3030-3039. PubMed ID: 35587865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
    PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.
    Faes C; Ilich A; Sotiaux A; Sparkenbaugh EM; Henderson MW; Buczek L; Beckman JD; Ellsworth P; Noubouossie DF; Bhoopat L; Piegore M; Renoux C; Bergmeier W; Park Y; Ataga KI; Cooley B; Wolberg AS; Key NS; Pawlinski R
    Blood; 2019 Jun; 133(23):2529-2541. PubMed ID: 30952675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Therapy as the New Frontier for Sickle Cell Disease.
    Garg H; Tatiossian KJ; Peppel K; Kato GJ; Herzog E
    Curr Med Chem; 2022; 29(3):453-466. PubMed ID: 34047257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving treatment paradigms in sickle cell disease.
    Jagadeeswaran R; Rivers A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):440-446. PubMed ID: 29222291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ineffective erythropoiesis in sickle cell disease: new insights and future implications.
    El Nemer W; Godard A; El Hoss S
    Curr Opin Hematol; 2021 May; 28(3):171-176. PubMed ID: 33631786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.